Abstract
We have described two cases of Devic's disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Brain / pathology
-
Female
-
Humans
-
Immunologic Factors / therapeutic use*
-
Magnetic Resonance Imaging / methods
-
Neuromyelitis Optica / drug therapy*
-
Neuromyelitis Optica / pathology
-
Neuromyelitis Optica / physiopathology*
-
Rituximab
-
Spinal Cord / pathology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Immunologic Factors
-
Rituximab